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Summary Introduction: The increasing clinical and microbiologic resistance of Can-
dida spp. isolates to several antifungal agents is becoming a serious problem. It is now
reasonable to propose the use of antifungal susceptibility testing in Candida spp. iso-
lates from patients who have failed conventional therapy, before the selection of an
empirical therapy.
Methods: One hundred and ﬁfty eight isolates of Candida spp. were evaluated simul-
taneously by broth microdilution (NCCLS standard) and well diffusion testing (WD), a
diffusion method similar to disc diffusion.
Results: According to the Wilcoxon Signed Ranks test performed, there was no
signiﬁcant difference (p > 0.05) between both methodologies for all antifungal agents
tested (ﬂuconazole, itraconazole, posaconazole, caspofungin and amphotericin B,
with C. tropicalis, C. krusei, C. dubliniensis, C. guillermondii, C. parapsilosis, C.
albicans and C. glabrata). A signiﬁcant difference was observed when comparing well
diffusion with NCCLS for ﬂuconazole WD 80% (p = 0.008) in C. glabrata, as well as WD
80% (p = 0.002) and WD 50% (p = 0.002) in C. albicans.
Conclusions: The well diffusion test is simple, easy to reproduce, inexpensive, easy
both to read and interpret, and has a good correlation to the reference NCCLS microdi-
lution test and may represent an alternative method for antifungal drug susceptibility
testing of Candida spp., mainly in laboratories with few resources.
© 2003 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
Introduction
Serious fungal infections in immunocompromised
patients are increasing in frequency and Candida
albicans and non-albicans species remain the most
common pathogens, with an increasing number of
*Corresponding author. Present address: Soﬁa Mata-Essayag,
Apartado Postal 47423, Caracas 1041, Venezuela.
Tel.: +58-5518465; fax: +58-6621082.
E-mail address: somae50@hotmail.com (S. Mata-Essayag).
clinical and/or microbiological resistance of these
species to several antifungal agents.1—10
It is now therefore reasonable to propose the
use of antifungal susceptibility testing in order to
analyze the causes of the failure of conventional
therapy in patients with Candida isolates or even
to predict ‘in vivo’ the response of mycoses to
antifungal agents. As new antifungal agents are
introduced for the treatment of infections caused
by yeasts, it is important that reliable methods are
available for the in vitro testing of both new and
established agents.
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Intensive efforts are being made to develop stan-
dardized, reproducible and clinically relevant sus-
ceptibility testing methods for yeasts but suscepti-
bility testing of fungi entails several methodologi-
cal problems. In 1997 the National Committee for
Clinical Laboratory Standards (NCCLS) published an
approved reference macrodilution method (docu-
ment M27-A) for in vitro testing.11 This document
describes a broth macrodilution method and its mi-
crodilution modiﬁcations. It is, however, laborious,
time consuming, requires specialized personnel and
has not eliminated the need for easier methods.
Currently other simpler and more economic meth-
ods for routine clinical tests are being developed.
Clearly, the disc diffusion method has the potential
to provide a simple means of performing in vitro
tests, but not all antifungal agents are available
in discs. Furthermore, the discs are very expen-
sive and their acquisition in developing countries is
sometimes difﬁcult. In an attempt to combat this,
in 1997 Magaldi developed a modiﬁcation of the
disc diffusion method which she named the ‘well
diffusion’ method (WD). The procedure is similar;
the discs are supplemented with dilutions of the
drug placed in wells which have been cut out in
the agar. This allows the use and standardization
of various concentrations of any drug for different
fungal species. It has proven to be a cheap, simple
and reliable method of antifungal drug susceptibil-
ity testing for Candida spp., and it produces results
comparable with the disc diffusion test.12—16
The aim of this study was to compare the well
diffusion method with the NCCLS broth microdilu-
tion method using several antifungal drugs includ-
ing two new antimycotic drugs: posaconazole and
caspofungin.
Materials and methods
Isolates
A total of 158 recent clinical isolates of Candida
spp. were studied. The isolates were submitted
Table 1 Antimycotic agents.
Licensed product generic name Producer Commercial name Solvent
Posaconazole (POS) Schering-Plough, Kenilworth, NJ PEG-400*
Itraconazole (ITC) Janssen Pharmaceutica, Titusville, NJ Sporanox DMSO**
Fluconazole (FLC) Pﬁzer Inc., New York, NY Diﬂucan H2O dest.
Amphotericin B (AMB) ER Squibb & Sons, Princeton, NJ Fungizone PEG-400*
Caspofungin (CAS) Merck & Co. Inc., Whitehouse, NJ Cancidas H2O dest.
* PEG-400 polyethylene glycol (Union Carbide, Danbury, CT)
** DMSO 100% dimethylsulfoxide (Sigma Chemical Co, St.Louis, MO)
to the Medical Mycology Section of the Instituto
de Medicina Tropical, UCV, Caracas, Venezuela,
for susceptibility testing. Thirteen control strains
were included with a known susceptibility pattern:
C. glabrata 90030, C. parapsilosis 22019, C. krusei
6258, C. albicans 90028 from the American Type
Culture Collection (ATCC) and C. tropicalis S594,
C. tropicalis S623B, C. albicans S621, C. albicans
623 and 5 C. dubliniensis (S-636, S2-14, S-645,
S2-6, S2-5) from the Health Science Center, Uni-
versity of Texas. The identiﬁcation of the isolated
yeast colonies was established by the production of
chlamydoconidia using modiﬁed Bilis agar, Feo,17
and carbon source assimilation reactions, using a
commercial kit, the API 32 C AUX identiﬁcation
system (BioMérieux). All isolates were subcultured
onto Sabouraud Dextrose agar, 24 hours prior to
identiﬁcation.
Antifungal susceptibility testing
Antifungal agents
The antifungal agents amphotericin B (AMB), caspo-
fungin (CAS), posaconazole (POS), itraconazole
(ITC), and ﬂuconazole (FLC) were used in their
commercial presentation to prepare a stock solu-
tion adjusted to the concentration of 1.25mgml−1
(25g per well). Each agent was dissolved in its
corresponding solvent (Table 1). No references are
available to determine the minimum inhibitory
concentration (MIC) of caspofungin. A test con-
centration of the drug necessary to visualize a
clear inhibition zone was performed. A serial so-
lution of caspofungin was prepared in distilled
water and adjusted to a ﬁnal concentration of
1.25mgml−1 (25g per well). In order to obtain
appropriate measurements for carrying out the
well diffusion and the NCCLS methods, MIC values
were measured in Casitone and RPMI media by NC-
CLS criteria (document M2711). MICs were deﬁned
as the lowest concentration which inhibited 100%
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Table 2 Antifungal susceptibility breakpoints against Candida sp. for NCCLS microdilution and well diffusion
methods.
Antifungal agent NCCLS Well diffusion
Susceptible
(gml−1)
Susceptible dose
dependent
(gml−1)
Resistant
(gml−1)
Susceptible
(mm)
Susceptible dose
dependent (mm)
Resistant
(mm)
Amphotericin B (AMB) ≤1 ≥1 ≥15 14—10 ≤9
Caspofungin (CAS)
Fluconazole (FLC) ≤8.0 16—32 ≥64
≥19 18—13 ≤12
Itraconazole (ITC) ≤0.125 0.25—0.5 ≥1
Posaconazole (POS)
of visible growth after 24 hours. The breakpoint
values for caspofungin obtained were comparable
to those of amphotericin B (Table 2). We com-
pared the baseline MIC with the microbiological
outcome.
NCCLS microdilution method
This method was used as described in the National
Committee for Clinical Laboratory Standards.11 All
the tests were performed twice. The MIC of ampho-
tericin B (MIC90) was deﬁned as the lowest concen-
tration resulting in a complete inhibition of growth.
The same results were obtained with caspofungin.
The MICs of all the other compounds (azoles) were
deﬁned as the lowest concentration which resulted
in a prominent decrease in turbidity compared with
that of growth-control wells, using the turbidity nu-
merical score proposed by the NCCLS (MIC50 and
MIC80).
Well diffusion method
The well diffusion test12—16 was performed using
Casitone agar18 (Bacto-casitone: 9 g; yeast ex-
tract: 5 g; tri-sodium citrate: 10 g; glucose: 20 g;
bactoagar: 15 g; phosphate buffer: KH2PO4: 1 g;
Na2HPO4: 1 g (Difco) (pH 6.6); H2O 1000ml). The
inoculum used was prepared using the yeasts from
a 24-hour culture on Sabouraud dextrose agar, a
suspension was made in a sterile saline solution
(0.85%). The turbidity of the suspension was ad-
justed with a spectrophotometer at 530 nm to
obtain a ﬁnal concentration to match that of a
0.5 McFarland standard (0.5—2.5× 103). 20ml of
Bacto-casitone were melted, cooled to 55 ◦C and
than inoculated with 1ml of the organism sus-
pension. The inoculated agar was poured into the
assay plate (9 cm in diameter), and allowed to
cool down on a leveled surface. Once the medium
had solidiﬁed, four wells, each 4mm in diameter,
were cut out of the agar, and 20l of the anti-
fungal agent were placed into each well. A total
of four antimycotics were placed into each plate
and incubated at 35 ◦C for 24 hours. Because of
disagreement over the criteria to determine the
end point of the diameters of the clear zone of in-
hibition of growth for the azoles, it was measured
both at 50% and 80%. However, NCCLS disc diffu-
sion breakpoints were used for the interpretative
breakpoints. The criteria used to determine MICs
were different for caspofungin and amphotericin B
because the diameters of the inhibition zones were
clear. A dramatic reduction in growth was observed
(>90%).
Overall, 158 clinical isolates were tested twice by
each method. Results were interpreted according
to NCCLS breakpoints for all the tests (Table 2),3,4
except for caspofungin (see antifungal agents).
Statistical analysis
A statistical analysis was performed with the per-
centage analysis and the Wilcoxon Signed Ranks
test (p > 0.05). There was signiﬁcant difference
between the two methodologies.
Results
One hundred and ﬁfty eight isolates of Candida
spp. were simultaneously evaluated by broth mi-
crodilution and well diffusion testing. A summary
of the frequencies of susceptible, dose dependent
and resistant isolates for both methods, is reported
in Tables 3 and 4. According to the Wilcoxon Signed
Ranks test performed, there was no difference be-
tween the methodologies for all antifungal agents
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Table 3 Frequency of susceptible and resistant iso-
lates of 158 Candida spp. with ﬂuconazole, itracona-
zole and posaconazole.
Drugs
FLC ITC POS
C. albicans (108 isolates)
WD 80%
S 73 76 82
DD 7 9 8
R 28 23 18
WD 50%
S 99 98 102
DD 3 3 1
R 6 7 5
NCCLS
S 82 81 87
DD 10 4 6
R 16 23 15
C. glabrata (30 isolates)
WD 80%
S 13 6 9
DD 6 9 6
R 11 15 15
WD 50%
S 17 9 12
DD 5 9 6
R 8 12 9
NCCLS
S 20 10 9
DD 4 9 7
R 6 11 16
C. tropicalis (7 isolates)
WD 80%
S 1 1 4
DD 1 2
R 6 5 1
WD 50%
S 1 2 5
DD 1 1 2
R 5 4
NCCLS
S 1 1 4
DD 2
R 6 6 1
C. dubliniensis (5 isolates)
WD 80%
S 5 5 5
DD
R
WD 50%
S 5 5 5
DD
R
NCCLS
S 5 5 5
DD
R
Table 3 (Continued )
Drugs
FLC ITC POS
C. krusei (4 isolates)
WD 80%
S 1 1 1
DD 1
R 3 3 2
WD 50%
S 1 1 2
DD 1 1
R 3 2 1
NCCLS
S 1
DD 1
R 4 4 2
C. parapsilosis (2 isolates)
WD 80%
S 2 2 2
DD
R
WD 50%
S 2 2 2
DD
R
NCCLS
S 2 2 2
DD
R
C. guillermondii (2 isolates)
WD 80%
S 1 1 2
DD
R 1 1
WD 50%
S 1 2
DD 1
R 1 1
NCCLS
S 1 2
DD
R 1 2
S = susceptible; DD = susceptible dose-dependent;
R = resistant; WD = well diffusion.
tested against C. tropicalis C. krusei, C. dublinien-
sis, C. guillermondii, C. parapsilosis, C. albicans
and C. glabrata (p > 0.05). There was, however,
a signiﬁcant difference observed when compar-
ing well diffusion with NCCLS, for ﬂuconazole WD
80% (p = 0.008) against C. glabrata and WD 80%
(p = 0.002) and WD 50% (p = 0.002) against C.
albicans.
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Table 4 Frequency of susceptible and resistant iso-
lates of 158 Candida spp. with amphotericin B and
caspofungin.
Drugs
AMB CAS
C. albicans (108 isolates)
WD 90%
S 106 108
DD
R 2
NCCLS
S 106 108
DD
R 2
C. glabrata (30 isolates)
WD 90%
S 29 30
DD 1
R
NCCLS
S 29 29
DD 1 1
R
C. tropicalis (7 isolates)
WD 90%
S 7 7
DD
R
NCCLS
S 7 7
DD
R
C. dubliniensis (5 isolates)
WD 90%
S 5 5
DD
R
NCCLS
S 5 5
DD
R
C. krusei (4 isotates)
WD 90%
S 4 4
DD
R
NCCLS
S 4 4
DD
R
C. parapsilosis (2 isolates)
WD 90%
S 2 2
DD
R
Table 4 (Continued )
Drugs
AMB CAS
NCCLS
S 2 2
DD
R
C. guillermondii (2 isolates)
WD 90%
S 1 1
DD 1 1
R
NCCLS
S 2 1
DD 1
R
S = susceptible; DD = susceptible dose-dependent;
R = resistant; WD = well diffusion.
Discussion
Methods for determining minimum inhibitory con-
centration (MIC) and interpretative breakpoint
guidelines for fungi were only recently
standardized.3,11—19,20—23 Due to their relatively
recent introduction and troublesome development,
antifungal susceptibility tests and clinical interpre-
tation remain somewhat controversial. As a result,
it can be difﬁcult to use antifungal susceptibility
test results to deﬁne resistance. Although there is
no consensus regarding the interpretation of break-
point values for all antifungal agents, the standard
NCCLS methods for antifungal susceptibility testing
are considered a reference method.11 Our geomet-
ric mean MICs for caspofungin against the tested
isolates were similar to those found by Pfaller.20
According to the Wilcoxon Signed Ranks test per-
formed, there was no signiﬁcant difference be-
tween both methodologies for all antifungal agents
tested with Candida spp. (p > 0.05), therefore this
simple well diffusion test is highly reproducible for
pathogenic yeasts and it strongly agrees with the
NCCLS method.
The discrepancy observed for ﬂuconazole WD
80% (p = 0.008) against C. glabrata as well as WD
50% (p = 0.002) and WD 80% (p = 0.002) against C.
albicans, when comparing the well diffusion test
with NCCLS may be due to inadequate end point
determination for ﬂuconazole, as can be observed
in the different results obtained by measuring 80%
or 50% inhibition of growth. Fluconazole shows a
diffuse zone of inhibition which is difﬁcult to read
and measure. It may be advisable to read well dif-
fusion for ﬂuconazole at 50% inhibition of growth
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as this gives a clearer zone of inhibition compared
to the NCCLS method.
In the group of Candida spp. studied with caspo-
fungin, even though no deﬁnite cut-off points for
caspofungin are yet established, we found that
the average measurement of the inhibition zone
diameter ﬁts better with the endpoint established
for amphotericin B by the disc diffusion method.
The inhibition (>90% reduction) zone diameters
of the well diffusion method were clear with a
good deﬁnition. They were easy to measure after
24 hours because of the homogeneous distribution
and growth of the strain obtained including the in-
oculum into the culture medium (Casitone) before
pouring onto the plate.
The use of both pure and commercial formula-
tions of the ﬂuconazole disc has been compared
to determine susceptibility of the Candida strains.
Magaldi et al.13 showed similar results for both pre-
sentations. Additionally, the use of the commercial
formulation also allows the testing of any drug and
the standardizing of various concentrations for dif-
ferent fungal species even when the discs for new
drugs are not yet commercially available or are too
expensive.
In previous studies the well diffusion method,
as compared to the reference method (NCCLS11),
showed a speciﬁcity of 100% for the susceptibility of
the strains to ﬂuconazole, with a positive predictive
value of 100%. Even though the sensitivity was only
84.85%, the high speciﬁcity allows the identiﬁcation
of all resistant strains. This may be helpful to the
physician when choosing a successful treatment.16
With well diffusion being a qualitative method, it
is very difﬁcult to establish the difference between
resistant strains and dose-dependent strains. The
NCCLS micro and macro broth dilution method is a
quantitative technique that allows the discrimina-
tion of these.
The comparison of the two methods showed that
the well diffusion test may represent an alternative
method for antifungal drug susceptibility testing
of Candida spp. using both new and established
agents, mainly in laboratories with few resources.
Nevertheless a clinical correlation needs to be
established.
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